Flow cytometry-assisted Monte Carlo simulation predicts clonogenic survival of cell populations with lognormal distributions of radiopharmaceuticals and anticancer drugs

References

• Akudugu JM, Neti PVSV, Howell RW. 2011. Changes in lognormal shape parameter guide design of patient-specific radiochemotherapy cocktails. Journal of Nuclear Medicine 52:642–649.
   PubMed Web of Science ®Google Scholar
• Aroui S, Brahim S, Waard MD, Kenani A. 2010. Cytotoxicity, intracellular distribution and uptake of doxorubicin and doxorubicin coupled to cell-penetrating peptides in different cell lines: A comparative study. Biochemical and Biophysical Research Communications 391:419–425.
   PubMed Web of Science ®Google Scholar
• Azure MT, Sastry KSR, Archer RD, Howell RW, Rao DV. 1992. Microscale synthesis of carboplatin labeled with the Auger emitter Pt-193m: Radiotoxicity versus chemotoxicity of the antitumor drug in mammalian cells. In: Howell RW, Narra VR, Sastry KSR, Rao DV, editors. Biophysical aspects of Auger Processes. Woodbury, NY: American Institute of Physics (http://www.aapm.org/pubs/books/default.asp). pp 336–351.
   Google Scholar
• Boucher KM, Yakovlev AY. 1997. Estimating the probability of initiated cell death before tumor induction. Proceedings of the National Academy of Sciences of the USA 94:12776–12779.
   PubMed Web of Science ®Google Scholar
• Charlton DE, Kassis AI, Adelstein SJ. 1994. A comparison of experimental and calculated survival curves for V79 cells grown as monolayers or in suspension exposed to alpha irradiation from 212Bi distributed in the growth medium. Radiation Protection Dosimetry 52:311–315.
   Web of Science ®Google Scholar
• Costantini DL, Villani DF, Vallis KA, Reilly RM. 2010. Methotrexate, paclitaxel, and doxorubicin radiosensitize HER2-amplified human breast cancer cells to the Auger electron-emitting radiotherapeutic agent 111In-NLS-Trastuzumab. Journal of Nuclear Medicine 51:477–483.
   PubMed Web of Science ®Google Scholar
• DeNardo SJ, Kukis DL, Kroger LA, O'Donnell RT, Lamborn KR, Miers LA, DeNardo DG, Meares CF, DeNardo GL. 1997. Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: Efficacy and toxicity in breast cancer xenografts. Proceedings of the National Academy of Sciences of the USA 94:4000–4004.
   PubMed Web of Science ®Google Scholar
• Durand RE. 1981. Flow cytometry studies of intracellular adriamycin in multicell spheroids in vitro. Cancer Research 41:3495–3498.
   PubMed Web of Science ®Google Scholar
• Gerlinger M, Swanton C. 2010. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. British Journal of Cancer 103:1139–1143.
   PubMed Web of Science ®Google Scholar
• Goddu SM, Rao DV, Howell RW. 1994. Multicellular dosimetry for micrometastases: dependence of self-dose versus cross-dose to cell nuclei on type and energy of radiation and subcellular distribution of radionuclides. Journal of Nuclear Medicine 35:521–530.
   PubMed Web of Science ®Google Scholar
• Hou DY, Hoch H, Johnston GS, Tsou KC, Jones AE, Farkas RJ, Miller EE, Larson SM. 1985. A new In-111 bleomycin complex for combined radiotherapy and chemotherapy. Journal of Surgical Oncology 29:91–98.
   PubMed Web of Science ®Google Scholar
• Howell RW, Rao DV, Sastry KSR. 1989. Macroscopic dosimetry for radioimmunotherapy: Nonuniform activity distributions in solid tumors. Medical Physics 16:66–74.
   PubMed Web of Science ®Google Scholar
• Howell RW, Kassis AI, Adelstein SJ, Rao DV, Wright HA, Hamm RN, Turner JE, Sastry KSR. 1994. Radiotoxicity of 195mPt labeled trans-platinum(II) in mammalian cells. Radiation Research 140:55–62.
   PubMed Web of Science ®Google Scholar
• Howell RW, Bishayee A. 2002. Bystander effects caused by nonuniform distributions of DNA-incorporated 125I. Micron 33:127–132.
   PubMed Web of Science ®Google Scholar
• Howell RW, Neti PV. 2005. Modeling multicellular response to nonuniform distributions of radioactivity: Differences in cellular response to self-dose and cross-dose. Radiation Research 163:216–221.
   PubMed Web of Science ®Google Scholar
• Humm JL. 1986. Dosimetric aspects of radiolabeled antibodies for tumor therapy. Journal of Nuclear Medicine 27:1490–1497.
   PubMed Web of Science ®Google Scholar
• Humm JL, Chin LM. 1993. A model of cell inactivation by alpha-particle internal emitters. Radiation Research 134:143–150.
   PubMed Web of Science ®Google Scholar
• Ickenstein LM, Edwards K, Sjoberg S, Carlsson J, Gedda L. 2006. A novel 125I-labeled daunorubicin derivative for radionuclide-based cancer therapy. Nuclear Medicine and Biology 33:773–783.
   PubMed Web of Science ®Google Scholar
• Kovtun YV, Audette CA, Mayo MF, Jones GE, Doherty H, Maloney EK, Erickson HK, Sun X, Wilhelm S, Ab O, . 2010. Antibody-maytansinoid conjugates designed to bypass multidrug resistance. Cancer Research 70:2528–2537.
   PubMed Web of Science ®Google Scholar
• Kvinnsland Y, Stokke T, Aurlien E. 2001. Radioimmunotherapy with alpha-particle emitters: Microdosimetry of cells with a heterogeneous antigen expression and with various diameters of cells and nuclei. Radiation Research 155:288–296.
   PubMed Web of Science ®Google Scholar
• Luk CK, Tannock IF. 1989. Flow cytometric analysis of doxorubicin accumulation in cells from human and rodent cell lines. Journal of National Cancer Institute 81:55–59.
   PubMed Web of Science ®Google Scholar
• Makrigiorgos GM, Ito S, Baranowska-Kortylewicz J, Vinter DW, Iqbal A, Van den Abbeele AD, Adelstein SJ, Kassis AI. 1990. Inhomogeneous deposition of radiopharmaceuticals at the cellular level: Experimental evidence and dosimetric implications. Journal of Nuclear Medicine 31:1358–1363.
   PubMed Web of Science ®Google Scholar
• Michel RB, Andrews PM, Castillo ME, Mattes MJ. 2005. In vitro cytotoxicity of carcinoma cells with 111In-labeled antibodies to HER-2. Molecular Cancer Therapeutics 4:927–937.
   PubMed Web of Science ®Google Scholar
• Neti PV, Howell RW. 2003. When may a nonuniform distribution of 131I be considered uniform? An experimental basis for multicellular dosimetry. Journal of Nuclear Medicine 44:2019–2026.
   PubMed Web of Science ®Google Scholar
• Neti PV, Howell RW. 2004. Isolating effects of microscopic nonuniform distributions of 131I on labeled and unlabeled cells. Journal of Nuclear Medicine 45:1050–1058.
   PubMed Web of Science ®Google Scholar
• Neti PV, Howell RW. 2006. Log normal distribution of cellular uptake of radioactivity: implications for biologic responses to radiopharmaceuticals. Journal of Nuclear Medicine 47:1049–1058.
   PubMed Web of Science ®Google Scholar
• Neti PV, Howell RW. 2008. Lognormal distribution of cellular uptake of radioactivity: Statistical analysis of alpha-particle track autoradiography. Journal of Nuclear Medicine 49:1009–1016.
   PubMed Web of Science ®Google Scholar
• Neti PVSV, Howell RW. 2007. Biological response to nonuniform distributions of 210Po in multicellular clusters. Radiation Research 168:332–340.
   PubMed Web of Science ®Google Scholar
• O'Donoghue JA. 1999. Implications of nonuniform tumor doses for radioimmunotherapy. Journal of Nuclear Medicine 40:1337–1341.
   PubMed Web of Science ®Google Scholar
• Pinto M, Howell RW. 2007. Concomitant quantification of targeted drug delivery and biological response in individual cells. BioTechniques 43(64):66–71.
   Google Scholar
• Rajon D, Bolch WE, Howell RW. 2011. Lognormal distribution of cellular uptake of radioactivity: Monte Carlo simulation of irradiation and cell killing in 3-dimensional populations in carbon scaffolds. Journal of Nuclear Medicine 52:926–933.
   PubMed Web of Science ®Google Scholar
• Rossi HH, Ellis RH. 1952. Calculations for distributed sources of beta radiation. American Journal of Roentgenology Radium Therapy and Nuclear Medicine 67:980–988.
   PubMedGoogle Scholar
• Saylor C, Dadachova E, Casadevall A. 2009. Monoclonal antibody-based therapies for microbial diseases. Vaccine 27(Suppl. 6):G38–46.
   PubMedGoogle Scholar
• Sharkey RM, Goldenberg DM. 2008. Use of antibodies and immunoconjugates for the therapy of more accessible cancers. Advances in Drug Delivery Reviews 60:1407–1420.
   PubMed Web of Science ®Google Scholar
• Shen S, Forero A, Meredith RF, Shah JJ, Knox SJ, Wiseman GA, Usrey ME, Lobuglio AF. 2010. Impact of rituximab treatment on 90Y-ibritumomab dosimetry for patients with non-Hodgkin lymphoma. Journal of Nuclear Medicine 51:150–157.
   PubMed Web of Science ®Google Scholar
• Song H, Sgouros G. 2011. Radioimmunotherapy of solid tumors: Searching for the right target. Current Drug Delivery 8:26–44.
   PubMed Web of Science ®Google Scholar
• Wessels BW, Rogus RD. 1984. Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies. Medical Physics 11:638–645.
   PubMed Web of Science ®Google Scholar
• Xue LY, Butler NJ, Makrigiorgos GM, Adelstein SJ, Kassis AI. 2002. Bystander effect produced by radiolabeled tumor cells in vivo. 99:13765–13770.
   Google Scholar